Get the Stockscreener App
19.53
12.07%
-2.68
After Hours:
19.58
0.05
+0.26%
Beam Therapeutics Inc stock is traded at $19.53, with a volume of 5.74M.
It is down -12.07% in the last 24 hours and down -25.85% over the past month.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
See More
Previous Close:
$22.21
Open:
$21.245
24h Volume:
5.74M
Relative Volume:
3.67
Market Cap:
$1.95B
Revenue:
$352.57M
Net Income/Loss:
$-143.01M
P/E Ratio:
-10.79
EPS:
-1.81
Net Cash Flow:
$-153.40M
1W Performance:
-18.66%
1M Performance:
-25.85%
6M Performance:
-20.29%
1Y Performance:
-40.89%
1-Day Range:
$18.30
$21.38
1-Week Range:
$18.30
$24.05
52-Week Range:
$18.30
$35.25
Beam Therapeutics Inc Stock (BEAM) Company Profile
Name
Beam Therapeutics Inc
Sector
Industry
Phone
857-327-8775
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
19.53 | 1.95B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-10-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Jan-29-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-23-24 | Initiated | H.C. Wainwright | Buy |
| Jan-29-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-08-23 | Downgrade | Jefferies | Buy → Hold |
| Oct-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-20-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-13-22 | Initiated | Citigroup | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Jan-05-22 | Initiated | Guggenheim | Buy |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Sep-24-21 | Resumed | Stifel | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Redburn | Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-16-21 | Initiated | Wells Fargo | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Aug-05-20 | Initiated | William Blair | Outperform |
| Mar-02-20 | Initiated | Barclays | Overweight |
| Mar-02-20 | Initiated | JP Morgan | Overweight |
| Mar-02-20 | Initiated | Jefferies | Buy |
| Mar-02-20 | Initiated | Wedbush | Outperform |
View All
Beam Therapeutics Inc Stock (BEAM) Latest News
Beam Therapeutics’ SWOT analysis: base editing pioneer faces gene therapy hurdles - Investing.com
The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics - Yahoo Finance
BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance - MSN
Beam Therapeutics (BEAM) Upgraded by BofA on Promising Genetic T - GuruFocus
Beam upgraded to Buy at BofA Securities on recent genetic condition treatment - Seeking Alpha
Beam Therapeutics stock rises after FDA clearance for BEAM-302 IND By Investing.com - Investing.com South Africa
Beam Therapeutics stock rises after FDA clearance for BEAM-302 IND - Investing.com
This Applied Materials Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Benzinga
B of A Securities Upgrades Beam Therapeutics (BMV:BEAM) - Nasdaq
B of A Securities Upgrades Beam Therapeutics (BEAM) - Nasdaq
Beyond The Numbers: 9 Analysts Discuss Beam Therapeutics Stock - Benzinga
BofA raises Beam Therapeutics stock rating to Buy, sets $42 target - Investing.com Canada
BofA Securities Upgrades Beam Therapeutics to Buy From Neutral - Marketscreener.com
FDA Clears Beam Therapeutics' (BEAM) Drug for Genetic Disease Tr - GuruFocus
Beam Therapeutics gets trial authorization for its genetic disorder treatment in U.S. - Seeking Alpha
Beam Therapeutics New Drug Application for Alpha-1 Antitrypsin Deficiency Gets FDA Clearance - Marketscreener.com
Beam Therapeutics’ BEAM-302 gains FDA’s nod for AATD treatment trial - Investing.com India
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration - The Manila Times
Beam Therapeutics’ BEAM-302 gains FDA’s nod for AATD treatment trial By Investing.com - Investing.com Australia
Beam Therapeutics Announces Clearance Of Investigational New Drug Application For BEAM-302 For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD) By The United States (U.S.) Food And Drug Administration - Marketscreener.com
Beam Therapeutics Announces Clearance of Investigational - GlobeNewswire
Beam Therapeutics (BEAM) Down 21.4% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Beam Therapeutics stock holds firm with $37 target at Bernstein By Investing.com - Investing.com South Africa
Cathie Wood’s ARK focuses on Beam Therapeutics, Intuitive Machines stock - Investing.com
Beam Therapeutics stock holds firm with $37 target at Bernstein - Investing.com
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen - Benzinga
Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy - Seeking Alpha
Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN) - The Globe and Mail
Beam Therapeutics’ $500 Million Common Stock Offering - Global Legal Chronicle
Trading (BEAM) With Integrated Risk Controls - Stock Traders Daily
Prime sets sights on liver, lung disease as next target for its gene editing tech - BioPharma Dive
3 Gene Therapy Stocks to Watch Amid Industry Turmoil - Schaeffers Research
Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study - MSN
Is Beam Therapeutics Inc. (BEAM) the Best Growth Stock to Invest in for the Next 10 Years? - Insider Monkey
BEAM Down Despite Positive Initial Data From Genetic Disorder Study - MSN
Wedbush Research Analysts Raise Earnings Estimates for BEAM - Defense World
Critical Survey: Adaptive Biotechnologies (NASDAQ:ADPT) vs. Beam Therapeutics (NASDAQ:BEAM) - Defense World
Citi lifts Beam Therapeutics stock price target to $64 - Investing.com India
Citi lifts Beam Therapeutics stock price target to $64 By Investing.com - Investing.com South Africa
Beam Therapeutics’ SWOT analysis: gene editing pioneer faces pivotal year for stock By Investing.com - Investing.com South Africa
Beam Therapeutics’ SWOT analysis: gene editing pioneer faces pivotal year for stock - Investing.com Australia
Beam Therapeutics Reports Clinical Proof-Of-Concept Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Trial - CRISPR Medicine News
Beam Therapeutics stock target holds at $37 on positive trial data - Investing.com Canada
Beam Base Editor’s Early Data in Rare Liver Disease Tee Up $500M Stock Sale in Tough Market - Dealbreaker
Beam Therapeutics Inc Stock (BEAM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):